Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells

Abstract

The A3 adenosine receptor, A3AR, belongs to the family of Gi proteins, which upon induction, suppresses the formation of cAMP and its downstream effectors. Recent studies have indicated that activation of A3AR by its agonist, IB-MECA, results in growth inhibition of malignant cells. Here we demonstrate the ability of IB-MECA to decrease the levels of protein kinase A, a downstream effector of cAMP, and protein kinase B/Akt in melanoma cells. Examination of glycogen synthase kinase 3β, GSK-3β, whose phosphorylation is controlled by protein kinase A and B, showed a substantial decrease in the levels of its phosphorylated form and an increase in total GSK-3β levels in IB-MECA treated melanoma cells. This observation suggests that the treatment of cells with IB-MECA augments the activity of GSK-3β in the cells. Evaluation of β-catenin, a key component of Wnt signaling pathway which, upon phosphorylation by GSK-3β rapidly ubiquitinates, showed a substantial decrease in its level after IB-MECA treatment. Accordingly, the level of β-catenin responsive cell growth regulatory genes including c-myc and cyclin D1 was severely declined upon treatment of the cells with IB-MECA. These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3β and β-catenin in the anti-tumor activity of A3AR agonists.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Ausubel F, Brent R, Kingston R, Moore D, Siedman JG, Smith JA, Struhl K . 1989 Current Protocols in Molecular Biology New York: John Wiley and Sons. pp 342–345

    Google Scholar 

  • Bar-Yehuda S, Barer F, Volfsson L, Fishman P . 2001 Neoplasia 3: 125–131

  • Bonvini P, Hwang SG, El-Gamil M, Robbins P, Kim JS, Trepel J, Neckers L . 2000 Biochim. Biophys. Acta. 1495: 308–318

  • Caballero OL, Sidransky D, Merbs SL . 2001 Invest. Ophthalmol. Vis. Sci. 42: 1679–1684

  • Cerni C . 2000 Mutat. Res. 462: 31–47

  • Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA . 1995 Nature 378: 785–789

  • D'Agnano I, Valentini A, Fornari C, Bucci B, Starace G, Felsani A, Citro G . 2001 Oncogene 20: 2814–2825

  • Diehl JA, Cheng M, Roussel MF, Sherr CJ . 1998 Genes Dev. 12: 3499–3511

  • Fang X, Yu SX, Lu Y, Bast Jr RC, Woodgett JR, Mills GB . 2000 Proc. Natl. Acad. Sci. USA 97: 11960–11965

  • Ferkey DM, Kimelman D . 2000 Dev. Biol. 225: 471–479

  • Filippa N, Sable CL, Filloux C, Hemmings B, Van Obberghen E . 1999 Mol. Cell. Biol. 19: 4989–5000

  • Fishman P, Bar-Yehuda S, Wagman L . 1998 Cancer Res. 58: 3181–3187

  • Fishman P, Bar-Yehuda S, Barer F, Multani AS, Pathak S . 2001 Exp. Cell Res. 269: 230–236

  • Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Multani AS . 2000 Eur. J. Cancer 36: 1452–1458

  • Gan D-D, Reiss K, Carrill T, Del Valle L, Croul S, Giordano A, Fishman P, Khalili K . 2001 Oncogene 20: 4864–4870

  • Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA . 2000 Mol. Cell. Biol. 20: 9356–9363

  • Linden J . 1991 FASEB J. 5: 2668–2676

  • McEwen DG, Peifer M . 2000 Curr. Biol. 10: 562–564

  • Miracco C, Pacenti L, Santopietro R, Biagioli M, Fimiani M, Perotti R, Rubegni P, Pirtoli L, Luzi P . 2000 Int. J. Cancer 88: 411–416

  • Morin PJ . 1999 Bioessays 21: 1021–1030

  • Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM . 1997 J. Biol. Chem. 272: 7713–7729

  • Novak A, Dedhar S . 1999 Cell Mol. Life Sci. 56: 523–537

  • Ohana G, Bar-Yehuda S, Barer F, Fishman P . 2000 J. Cellular Physiol. 186: 19–23

  • Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA . 1996 Exp. Med. 183: 1185–1192

  • Sable CL, Filippa N, Hemmings B, Van Obberghen E . 1997 FEBS Lett. 409: 253–257

  • Stiles GL . 1990 Clin. Res. 38: 10–18

  • Zhao Z, Makaritsis K, Francis CE, Gavras H, Ravid K . 2000 Biochim. Biophys. Acta. 1500: 280–290

Download references

Acknowledgements

We thank Dr Jennifer Gordon for her insightful contributions to this work and Ms C Schriver for editorial assistance And preparation of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pnina Fishman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fishman, P., Madi, L., Bar-Yehuda, S. et al. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21, 4060–4064 (2002). https://doi.org/10.1038/sj.onc.1205531

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205531

Keywords

This article is cited by

Search

Quick links